Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease

Core Insights - Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to develop blood-based biomarkers for tau pathology in Alzheimer's disease, aiming to enhance patient stratification and treatment monitoring [1][2][3] Company Summaries Biogen - Founded in 1978, Biogen is a leading biotechnology company focused on innovative science to deliver new medicines and create value for shareholders and communities [4] - The company will provide Alzheimer's clinical study data and expertise in biomarker research to prioritize markers for tau pathology in the collaboration [3] Beckman Coulter - Beckman Coulter has over 80 years of experience in advanced diagnostics, aiming to improve patient health through innovative diagnostic solutions [5][6] - The company will be responsible for diagnostic development, manufacturing, and commercialization in the collaboration [3] Fujirebio - Fujirebio, part of H.U. Group Holdings Inc., has over 50 years of experience in in vitro diagnostics and aims to develop novel neurodegenerative disease diagnostics [7] - The company will collaborate to accelerate the development of blood-based biomarkers for tau pathology and deliver them globally [3]